{"data":{"id":1608,"lang":"en","title":"Eli Lilly Mounjaro Overtakes Merck Keytruda as World's Top-Selling Drug With $8.7 Billion in Q1 2026","summary":"Mounjaro generated $8.7 billion in Q1 2026 versus Keytruda's $7.9 billion, ending Merck's three-year reign as the maker of the world's top-selling drug.","category":"business","category_label":"Business","published_at":"2026-05-08T02:01:11Z","updated_at":"2026-05-08T02:01:11Z","url":"https://techtools.cz/tools/news/article/1608-eli-lilly-mounjaro-overtakes-merck-keytruda-as-world-s-top-selling-drug-with-8","api_url":"https://techtools.cz/news-api/v1/articles/1608?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1608.md?lang=en","image_url":"https://bostonglobe-prod.cdn.arcpublishing.com/resizer/v2/IHKOO4WQZVDSPKNGVKCSOMHZ4I.jpg","word_count":140,"reading_time_minutes":1,"sources":[{"url":"https://www.bloomberg.com/news/articles/2026-05-06/lilly-s-mounjaro-overtakes-merck-s-king-keytruda-as-world-s-top-selling-drug","domain":"bloomberg.com"},{"url":"https://www.bostonglobe.com/2026/05/06/business/lillys-mounjaro-overtakes-keytruda-worlds-top-selling-drug/","domain":"bostonglobe.com"},{"url":"https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines-302758113.html","domain":"prnewswire.com"}],"translation":{"lang":"cs","id":1681,"title":"Mounjaro od Eli Lilly předstihl Keytrudu od Mercku jako nejprodávanější lék světa s tržbami 8,7 miliardy dolarů v 1. čtvrtletí 2026","url":"https://techtools.cz/tools/news/clanek/1681-mounjaro-od-eli-lilly-predstihl-keytrudu-od-mercku-jako-nejprodavanejsi-lek","api_url":"https://techtools.cz/news-api/v1/articles/1681?lang=cs"},"content":"Eli Lilly's diabetes drug Mounjaro has dethroned Merck's cancer therapy Keytruda as the world's best-selling medication, generating $8.7 billion in Q1 2026 versus Keytruda's $7.9 billion. Keytruda had held the top spot since Q1 2023, when it displaced AbbVie's autoimmune drug Humira.\n\nU.S. Mounjaro revenue hit $4.2 billion, up 59% year-over-year, while international sales surged to $4.4 billion from just $1.2 billion in Q1 2025. The international jump was driven by Mounjaro's addition to China's National Reimbursement Drug List, opening access to the world's second-largest pharmaceutical market.\n\nCombined with Zepbound, which shares the same active ingredient tirzepatide, Lilly's GLP-1 franchise generated $36.5 billion in 2025 versus Keytruda's $31.6 billion. Lilly raised its full-year 2026 revenue guidance on the back of the dominant Q1 print, despite pricing pressure from the Trump administration and competition from compounded copycat versions during prior shortages."}}